AI models need more data about biology, and OpenAI is paying to create it

Last year, the clinical trial policy analyst Ruxandra Teslo posted an idea for super-charging medical AI systems: use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, an